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Abstract
Background: Art Therapy has been promoted as a means of helping people who may find it difficult to express
themselves verbally engage in psychological treatment. Group Art Therapy has been widely used as an adjunctive
treatment for people with schizophrenia but there have been few attempts to examine its effects and cost
effectiveness has not been examined. The MATISSE study aims to evaluate the clinical and cost effectiveness of
group Art Therapy for people with schizophrenia.
Method/Design: The MATISSE study is a three-arm, parallel group, pragmatic, randomised, controlled trial of
referral to group Art Therapy plus standard care, referral to an attention control ‘activity’ group plus standard care,
or standard care alone. Study participants were recruited from inpatient and community-based mental health and
social care services at four centres in England and Northern Ireland. Participants were aged over 18 years with a
clinical diagnosis of schizophrenia, confirmed by an examination of case notes using operationalised criteria.
Participants were then randomised via an independent and remote telephone randomisation service using
permuted stacked blocks, stratified by site. Art Therapy and activity groups were made available to participants
once a week for up to 12 months. Outcome measures were assessed by researchers masked to allocation status at
12 and 24 months after randomisation. Participants and care givers were aware which arm of the trial participants
were allocated to. The primary outcomes for the study are global functioning (measured using the Global
Assessment of Functioning scale) and mental health symptoms (measured using the Positive and Negative
Syndrome Scale) assessed at 24 months. Secondary outcomes were assessed at 12 and 24 months and comprise
levels of group attendance, social function, satisfaction with care, mental wellbeing, and costs.
Discussion: We believe that this is the first large scale pragmatic trial of Art Therapy for people with schizophrenia.
Trial registration: Current Controlled Trials ISRCTN46150447
Background
Schizophrenia is a severe mental disorder which affects
as many as one in 100 people at some point in their
lives [1]. In addition to ‘positive’ symptoms of schizo-
phrenia such as hallucinations and delusions, many peo-
ple also experience varying degrees of loss of energy,
impaired attention, reductions in the amount and con-
tent of speech and other so-called ‘negative’ symptoms
[2]. While antipsychotic medication reduces the
symptoms of schizophrenia and decreases the likelihood
of relapse [3], many people do not adhere to treatment
and a substantial proportion of those who do experience
residual symptoms, relapse and reduced social function-
ing [4,5]. Psychological and social interventions are
widely used in combination with pharmacotherapy in an
effort to further improve the health and social outcomes
of people with schizophrenia and several have been
shown to be effective [6].
Art Therapy is a form of psychotherapy that has been
practised for over 60 years [7]. It has been promoted as
a means of helping people who may find it difficult to
express themselves verbally engage in psychological
* Correspondence: m.crawford@imperial.ac.uk
1Centre for Mental Health, Imperial College, Claybrook Road London,
W6 8LN, UK
Full list of author information is available at the end of the article
Crawford et al. BMC Psychiatry 2010, 10:65
http://www.biomedcentral.com/1471-244X/10/65
© 2010 Crawford et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
treatment. In Art Therapy people are provided with a
choice of art materials and encouraged to use them to
express themselves freely. It has been argued that Art
Therapy has advantages over traditional psychotherapies
because the images that a person makes can help a per-
son understand themselves better whilst also containing
powerful feelings that might otherwise overwhelm them
[8]. The key ingredients of Art Therapy are considered
to be the process of making art, and the relationship
that develops between the therapist and the participant
[9]. In group Art Therapy, there is also the potential to
explore and utilise the experience of other relationships
between group members [10].
Despite the widespread use of group Art Therapy for
people with schizophrenia little research has been con-
ducted to explore its effects [11]. Green and colleagues
conducted a randomised trial of 10 weekly sessions of
group Art Therapy plus standard care versus standard
care alone among 47 people with ‘chronic psychiatric
disorders’ of whom half had a clinical diagnosis of schi-
zophrenia [12]. At 10-week follow-up those allocated to
group Art Therapy reported improved self esteem. More
recently, Meng and colleagues randomised 86 in-
patients to twice weekly group Art Therapy delivered
over 15 weeks and reported improved health and social
functioning at the end of this period [13]. Richardson
and colleagues [14] compared the addition of 12 weekly
sessions of group Art Therapy to standard care among
people with chronic schizophrenia being treated in out-
patient settings. Among 40 (45%) participants who were
followed up at six months, statistically significant reduc-
tions in negative symptoms were found.
However, in their systematic review of the effective-
ness of Art Therapy for people with schizophrenia,
Ruddy and Milnes [15] concluded that because of small
sample sizes, short follow-up periods, and high rates of
loss to follow-up, the benefits and potential harms of
Art Therapy for people with schizophrenia are still
unclear. Moreover because previous studies have not
incorporated attention control groups there is no evi-
dence regarding the relative contribution of non-specific
components and ‘active ingredients’ of the intervention
to observed outcomes. Nor has previous research exam-
ined the costs or cost effectiveness of this intervention.
Research objectives
The objectives of the study are to examine the impact of
referral to group Art Therapy plus standard care in peo-
ple with schizophrenia compared to referral to attention
control treatment plus standard care or standard care
alone on health and social functioning and to compare
the costs and cost effectiveness of adding group Art
Therapy to a person’s existing treatment.
The study hypotheses are that, among people with
schizophrenia;
i) Referral to group Art Therapy is associated with
improved global functioning at 24 months compared to
referral to attention control treatment or standard care
alone.
ii) Referral to group Art Therapy is more cost-effective
than referral to attention control treatment or standard
care alone.
iii) Referral for group Art Therapy is associated with
improved mental health, social functioning, well-being
and satisfaction with care compared to referral for atten-
tion control treatment or standard care alone.
iv) Those referred to group Art Therapy will attend a
greater proportion of the groups available to them than
those referred to activity groups.
Our primary hypothesis is based on global functioning
and symptoms of psychosis at 24 months. We have
selected this time point because previous studies of psy-
chosocial interventions for people with schizophrenia
have demonstrated greater improvements in global func-
tioning in the period after the end of therapy [16,17].
Methods
Trial design
The MATISSE study (Multi-centre study of Art Therapy
In Schizophrenia - Systematic Evaluation) is a three-
arm, parallel group, pragmatic, randomised, controlled
trial of referral to group Art Therapy plus standard care,
referral to an attention control ‘activity’ group plus stan-
dard care, or standard care alone. Similar numbers of
participants were randomised to each of the three arms
of the trial. We aimed to use a pragmatic design which
would allow us to test the impact of referring people to
group Art Therapy in normal clinical practice.
Three changes were made to the design of the study
after commencement. Firstly, because recruitment was
slower than anticipated the period for recruiting the
study sample was increased from nine to 20 months
[18]. Secondly, following publication of national gui-
dance on the treatment of schizophrenia highlighting
the importance of arts therapies in treating symptoms
of schizophrenia [19], we promoted total symptom
score as a co-primary outcome measure. Finally, early
data demonstrating lower levels of attendance at
groups than we anticipated led us to increase the total
number of participants to 10% above our original tar-
get. Ethical approval for the study, including these
protocol amendments, was given by Huntingdon
Research Ethics Committee (06/Q0104/82) and the
study protocol was registered with Controlled Clinical
Trials (ISRCTN46150447) prior to the start of data
collection.
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Study setting and sample
Study participants were recruited from four UK centres,
three in England (West London, North London, and
Avon & Wiltshire) and one in Northern Ireland (Bel-
fast). Centres were selected because they had systems
for delivering group Art Therapy to people with schizo-
phrenia and for supervising and supporting arts thera-
pists. The centres cover a mix of inner city, urban,
semi-rural and rural areas and serve a population that
includes people from a variety of different ethnic
backgrounds.
We recruited participants from secondary care settings
including inpatient units, day hospitals, community
mental health teams, rehabilitation services, supported
accommodation and day centres. To take part in the
study people had to be aged 18 years or over and have a
clinical diagnosis of schizophrenia, confirmed by an
examination of case notes using operationalised criteria
(OPCRIT) [20]. Exclusion criteria were minimised to
increase the generalisability of study findings. A list of
all inclusion and exclusion criteria is presented in Table
1. While people who were currently receiving Art Ther-
apy or another of the arts therapies (Music, Drama
Therapy etc) were excluded from the study, those who
were in receipt of other forms of structured psychosocial
intervention were included.
Study interventions
The MATISSE trial has three treatment conditions:
referral to group Art Therapy plus standard care, refer-
ral to an activity group plus standard care, and standard
care alone. The guidance given to group facilitators on
processes and response to adverse events of Art Therapy
and activity groups used in the trial is summarised in
Tables 2 and 3.
Group Art Therapy
Those randomised to group Art Therapy were offered
weekly sessions of 90 minutes of duration for a period
of 12 months. We planned that no group would have
more than eight ‘active’ members, though more than
eight people were sometimes referred when those allo-
cated did not engage (see table 2). All groups were led
by art therapists registered with the Health Professions
Council who had previous experience working with peo-
ple with psychosis. Groups were co-facilitated by
another member of staff or a volunteer.
Group Art Therapy was conducted in keeping with
recommendations of the British Association of Art
Therapists [21]. The key ingredients of group Art Ther-
apy are considered to be the process of art making, and
the tri-partite relationship which involves therapist, par-
ticipant and image [9]. The groups aim to give people
the potential to explore and utilise the experience of
other relationships between group members [10]. A
range of art materials was available in each group and
participants were encouraged to use them to express
themselves freely and spontaneously. Relationships
within the group were considered in relation to both
conscious and unconscious processes. Art therapists
generally adopted a supportive approach, offering empa-
thy and encouragement. They rarely provided symbolic
interpretations of inter-personal process or images. They
did however frequently discuss these processes in super-
vision. Within this framework, therapists employed a
range of interventions thought appropriate to each parti-
cipant. This approach is in keeping with recommenda-
tions for the pragmatic evaluation of complex
interventions [22] in which individual therapists are
encouraged to apply treatment principles flexibly to fit
with the needs of participants [23].
Activity groups
Activity groups were designed to control for the non-
specific effects of group Art Therapy; identified as struc-
tured time with an empathic professional and opportu-
nities for interaction with peers in a group setting. They
were also designed to reflect the kind of activity-based
groups currently provided by mental health and social
care services for people with psychosis in the UK. Allo-
cated participants were offered a place in a weekly activ-
ity groups of for up to 90 minutes duration for a 12
month period. No group had more than eight members,
though more than eight people could be referred to a
group to support membership up to this level. All lead
facilitators had previous experience of working with
people with psychosis in groups and all groups were co-
facilitated by another member of staff or volunteer.
Group facilitators offered various activities to mem-
bers and encouraged participants to collectively select
activities for the group. Activities included themed dis-
cussion, board games, watching and discussing DVDs,
visits to local cafes and occasional visits to places of
Table 1 Inclusion and exclusion criteria for the MATISSE study
Inclusion criteria Exclusion criteria
Aged 18 years or over Already receiving Art Therapy or another arts therapy (Music Therapy, Drama
Therapy, or Dance/Movement Therapy)
Clinical diagnosis of schizophrenia confirmed using
operationalised criteria (OCRIT) [20]
Severe cognitive impairment
Willing to provide written informed consent.
Willing to take part in trial therapies
Inability to speak sufficient English to complete the baseline assessment
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Table 2 Group processes and response to adverse events used in the trial
Aspect of structure or content of
groups
Aspects shared by Art Therapy and activity groups
Engaging with the group Group facilitators should contact new members by post and or telephone to invite them to the group and
provide them with details of location, start times etc. Facilitators should try to meet participants on one
occasion before they commence the group to outline aims, protocol boundaries and expectations. This may
be done either individually or in groups
Group member leaves the group When a group member specifically tells the facilitator that that they do not want to attend the group, or
when they have not attended the group for a number of weeks without there being a clear reason for the
facilitator should use their clinical judgement to make a decision about when they should be considered as
having left the group. At this stage the facilitator will write to the patient confirming that their place in the
group has closed
Replacing a group member with
another patient
When it is agreed that a patient has left the group the facilitator should notify the trial coordinator who will
make a note that there is a space in the group that can be filled by another study participant
Verbal aggression or violence Facilitator to obtain and refer to risk assessment for all group members prior to their joining. In case of
agitation/aggression/violence, the facilitator should use their clinical judgement to assess the situation and
attempt de-escalation. The group member may need to be asked to leave the room. Inform the patient’s care-
coordinator, document the incident on the treatment fidelity proforma and complete incident form etc (as
per usual clinical practice). Patients may be asked to stay away from subsequent groups (such a decision
should be discussed with clinical supervisor)
Deteriorating mental state Where a participant’s mental state shows clear signs of deteriorating the facilitator should encourage the
patient to discuss this with their care coordinator or psychiatrist. If the situation continues to deteriorate the
facilitator should seek verbal consent from the patient to contact their care coordinator. In consultation with
their supervisor and following review of their risk assessment and care plan, there may be circumstances in
which the facilitator will need to contact the patient’s care coordinator even if consent is withheld
Therapist leaves local services OR
sick leave etc
When long gaps look likely the situation should be discussed with the local supervisor and efforts made to
identify a new facilitator. Participants should be given as much notice of this as possible
Table 3 Differences in group processes and response to adverse events in Art Therapy and activity groups used in the
trial
Aspect of structure
or content
Activity Groups Art Therapy groups
Late attendance Remind client about starting times Use clinical judgement when deciding how to explore
reasons for late attendance/feelings about the group
Conflict with facilitator/
therapist or other
group members
Make efforts to help the patient calm themselves, try to
refocus patient on group activities, and try to take steps to
avoid escalation of the situation
Use clinical judgement to enquire about reasons for conflict
and understand the behaviour in terms of their art work,
group processes, and other factors in the patient’s life
Annual leave/sick leave MATISSE group supervisors should discuss this with
individual group facilitators but we suggest that every
attempt is made to avoid absence of facilitators during the
first few weeks of the study. Once a group has become
established short periods of leave should be managed by
the co-facilitator
If the art therapist is unable to attend the group the group
will be cancelled
Wherever possible the group will be notified in advance and
space provided for members to process this
Handling psychological
material
If participants raise psychological concerns these should be
handled in a sensitive, client-centred manner by the
facilitator. Diversionary methods may be used to help
participants focus on group activities as a means of
distracting themselves from their symptoms. Participants
may also be encouraged to raise their concerns with their
key worker
Art therapists should use their clinical judgement to decide
how to help participants express themselves both verbally
and through use of images. Experiences of distress may be
considered in the context of factors occurring in their lives
and the outside world, but may also be thought about in
relation to group processes and their use of art materials.
While therapists may sometimes suggest links between art
work and the persons’ mental state or history, therapy is
generally focussed on the ‘here and now’. Efforts to address
the content and meaning of art work produced by a person
who is acutely psychotic need to be handled with utmost
sensitivity or avoided
Psychological concerns will not be explored in these groups
and interpretations of participants’ behaviours or comments
must not be provided
Group facilitator leaves Changes in group facilitator should be explained ahead of
any change wherever possible
Opportunities for exploring participants’ feelings about
changes of facilitator should be made available
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interest. The use of art and craft materials was prohib-
ited. Group facilitators were asked not to engage partici-
pants in therapeutic conversation. Where necessary, if
for example participants became distressed or wanted to
discuss clinical concerns, facilitators employed diversion
and/or encouraged participants to take up any specific
concerns with professionals already involved in their
care.
Prior to entry into groups art therapists and activity
group facilitators met participants individually or in
small groups to provide information about the group
and promote engagement. Telephone and postal contact
with participants and those involved in their care was
used to promote engagement and retention in groups.
Standard care
Standard care involved follow-up from secondary care
mental health services, care coordination, pharmacother-
apy and the option of referral to other services. No
restrictions were imposed on referral to other services
apart from arts therapies which participants agreed not
to use until the final follow-up assessment had been
completed.
Treatment fidelity
Facilitators of all Art Therapy and activity groups com-
pleted a short proforma at the end of each group. The
form required the facilitator to note the structure and
content of the group including: the names and number
attending and duration of attendance, any breaches of
group boundaries and how these were addressed, the
verbal content of sessions and responses made by group
facilitators to verbal content. For Art Therapy groups,
therapists were also asked to record the art materials
made available and used by the group, and for activity
groups facilitators were asked to record the principal
activities pursued.
All art therapists and facilitators of activity groups
attended an orientation meeting at the start of the
study. The background and methods of the project were
presented and general principles for facilitating groups,
arrangements for supervision, and the role of study pro-
forma were discussed. During the treatment phase of
the trial, art therapists and activity group facilitators
received local monthly group supervision. Supervision
sessions were audio-recorded and recordings reviewed
by a senior member of the study team who provided
feedback to supervisors regarding adherence to general
guidelines as presented in Table 2.
At the end of the study, proforma from all centres
were collected by the research team and a random sam-
ple of 50 (25 from Art Therapy groups and 25 from
activity groups) per study centre (i.e. 200 in total) were
examined for treatment fidelity. Data on ’verbal content
of sessions and responses made by group facilitators’
were extracted. Specific references to the type of group
were removed and a senior member of the study team,
masked to what type of group the data was extracted
from, rated each extract as coming from either an Art
Therapy group or an activity group.
Measures
At baseline, demographic and clinical data were col-
lected including; age, gender, ethnicity, highest level of
educational achievement, employment status, housing
status, date of first presentation to clinical services with
schizophrenia, primary and any secondary clinical diag-
nosis, current medication, and previous receipt of struc-
tured psychosocial interventions including arts
therapies. Written records and in some cases collateral
information gathered from carers or health professions
were used to generate a psychiatric diagnosis using
operationalised criteria [20]. Primary and secondary out-
come measures are listed below. Each measure was
assessed at recruitment (baseline), one year and two
year follow-up. Measures were completed either by the
researcher, the participant or by their key worker as
indicated below.
Completed by the researcher
i) Global functioning (co-primary outcome) - was
assessed using the Global Assessment of Functioning
Scale (GAF), a 100-point single item, observer-rated
scale that rates functioning on a continuum from health
to illness. It is a reliable and valid measure of global
functioning that has been widely used in previous stu-
dies of people with schizophrenia and is sensitive to
change [24].
ii) Mental health (co-primary outcome) - was assessed
using the Positive and Negative Syndrome Scale [25].
This is a 30-item rating scale which is accompanied by
a structured interview. It takes approximately 30 min-
utes to complete and has been widely used to examine
changes in symptoms in people with schizophrenia and
related psychoses.
iii) Medication - was recorded all medication being
prescribed to participants and assessed concordance
using the Morisky Scale a four item questionnaire which
provides a valid estimate of use of psychotropic medica-
tion [26].
iv) Health related quality of life - was assessed using
Euroqol EQ-5 D [27]. This is a generic measure for
describing and valuing health-related quality of life
assessed in five domains (mobility, self-care, usual activ-
ities, pain/discomfort, anxiety/depression).
v) Cost data - was assessed using a modified version of
the Adult Service Use Inventory which was designed on
the basis of previous studies in adult mental health
populations [28,29] and adapted for the purpose of this
study.
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Completed by the participant
vi) Social Function - was assessed using the Social Func-
tion Schedule [30], a widely used self-completed mea-
sure of social function with established reliability and
validity.
vii) Wellbeing was assessed using the General Well-
Being Scale. This 18 item, self-report instrument was
originally developed for the US Health and Nutrition
Survey, but has subsequently been used in studies of
people with schizophrenia and has good psychometric
properties [31].
viii) Satisfaction with mental health services - was
assessed using the Client Satisfaction Questionnaire, an
eight-item measure that has been widely used in pre-
vious studies and is sensitive to change [32].
Completed by the participants’ key worker
ix) Engagement with mental health services was assessed
using the four-item Service Engagement Scale [33].
x) Data on occupational and housing status were gath-
ered indicating whether the participant lived in indepen-
dent or supported accommodation (and the degree of
support provided), together with a short description of
any paid work, voluntary work or educational/training
activities undertaken by the participant during the pre-
vious six months.
xi) Any incidents of suicidal behaviour, violence or
aggression in the previous year were recorded using a
proforma based on the one used by Johnson and collea-
gues [34].
xii) Global functioning using the Global Assessment of
Functioning Scale (GAF) [24]
was rated by the researcher in instances where it was
not possible for them to complete a face-to face assess-
ment of the participant. A ‘proxy GAF’ based on best
available information from whatever contact they had
had with the participant, key informants and clinicians
was made.
Following the collection of all 24-month follow-up
data, participants’ electronic and written records were
examined to obtain details of any period of inpatient
treatment received during the previous two years.
Study procedures
In each centre researchers publicised the study through
meetings with staff at local inpatient units, community
teams, day centres and residential units. Researchers vis-
ited these teams on a regular basis to remind staff about
the study and promote recruitment of potential partici-
pants. Researchers were assisted in this by clinical stu-
dies officers of the UK Mental Health Research
Network. Clinical staff were given a copy of an informa-
tion sheet which summarised the study protocol and
helped them identify patients who may be suitable for
the study. Researchers met those who had given verbal
consent to be approached about the study, assessed elig-
ibility, provided written and verbal information, obtained
written consent, and collected baseline data. Participants
were then randomised via an independent remote tele-
phone randomisation service using permuted stacked
blocks, stratified by site. The block size was randomly
assigned between three and six. Each element within the
block was randomly assigned to one of the three treat-
ments in proportion to the size of the block.
Participants, their key worker and their general practi-
tioner were notified of allocation status by an indepen-
dent administrator. The administrator simultaneously
informed local art therapists or activity group facilitators
of the allocation status of the participant so that
arrangements could be made for the participant to
receive their allocated intervention while researchers
involved in collecting follow-up data remained masked.
Rater ‘masking’ was maintained by providing specific
instructions to participants and their clinical teams not
to disclose treatment details. Data are held securely and
all personal identifiers removed, with randomisation
details held separately and password protected. Data on
participants’ uptake of the trial interventions was moni-
tored through proforma completed by group facilitators
after each group as described above. Thus researchers
did not have to record this information from case files
as this would have led to unmasking. Participants com-
pleting follow-up interviews were offered a £15 honorar-
ium in recognition of their time in completing research
interviews and any inconvenience related to their invol-
vement in the study.
Sample size
The sample size calculation for the study was based on
the primary hypothesis: that those referred to group Art
Therapy will have improved global functioning at 24
months compared to those referred to attention control
treatment or standard care alone. Global functioning
had not been assessed in randomised trials of Art Ther-
apy for people with schizophrenia that had been com-
pleted when the study was being planned, so data on
mean GAF scores and standard deviations were taken
from previous trials of Compliance Therapy and Cogni-
tive Therapy for people with schizophrenia. These inter-
ventions demonstrate an improvement in GAF scores of
between five and 10 points [16,17]. We powered this
trial to be able to detect a difference in GAF score of
six points.
To detect a mean difference in global functioning of
six points on the GAF (SD = 10.0) at 24 months with a
two-sided significance level (a) of 5% and power of 80%
would require 45 patients in each arm of the trial. In
trials of complex interventions there is likely to be clus-
tering of the intervention effect within therapists. In our
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recent trial of music therapy for people with schizophre-
nia we observed an intra-class correlation coefficient
(ICC) of 0.125 [35]. However we anticipated that group
processes may lead to a greater clustering of effects and
decided to use an ICC of 0.175 for this trial. With an
estimated cluster size of 8 and an ICC of 0.175 the
Design Effect for the trial is 2.22 and a sample size of
100 per group was therefore required. A sample of 100
participants in each of the three arms of the trial would
be sufficient to detect a difference of 50% in mean costs,
at the 5% level of significance and with 80% power. In
anticipation of a 20% loss to follow up at 24 months, we
planned to randomise 376 participants, 94 at each
centre.
Statistical analysis
All primary statistical analysis will use the intention-to-
treat principle. The statistical package STATA (version
11.0) will be used for all the analyses. The numbers
(with percentages) of losses to follow-up at 12, and 24
months after randomisation will be reported and com-
pared between the treatment arms with absolute risk
differences (95% Confidence Intervals); any deaths and
their causes will be reported separately.
For our main analysis we will impute baseline missing
covariates using either mean or regression imputation to
increase power and precision of the estimated treatment
effect [36]. We will use all available results without
imputation of missing outcomes. For the continuous
outcomes, differences in mean score between those ran-
domised to each of the three arms of the trial will be
examined using analysis of covariance adjusting by 1)
site and baseline value of outcome 2) site, baseline value
of the outcome, sex and age. The assumption of linear-
ity will be assessed by residual analysis; if necessary
bootstrapping techniques will be employed.
Two sensitivity analyses will be conducted to take into
account missing data 1) multiple imputation, which
assumes data are ‘missing at random’, and 2) replace-
ment of the missing GAF scores with those from the
GAF proxy measure that we collected from participants’
key workers.
We anticipate that there will be clustering of outcomes
as a result of patients being assigned to groups facilitated
by different therapists in different sites. Such clustering
violates the assumption that observed outcomes of indivi-
duals are independent and can result in increased stan-
dard errors [37,38]. To take account of this we will
explore separately therapist and site as random effects
and finally a three-level model will be fitted, with patients
as level one, therapist as second level, and the site as the
third level. If our conclusions depend on which model is
adopted we will present all results in the principal paper.
In a secondary analysis we will examine the impact of
the level of uptake of groups using Complier Average
Causal Effect analysis [39]. Instrumental variable meth-
ods will be used to model our outcome adjusting for
age and sex. Randomisation allocation will be used as an
instrumental variable.
The health economic evaluation will be conducted
from the societal perspective, covering services received
and any productivity losses. Differences in mean costs
will be analysed using standard parametric t-tests with
the validity of results confirmed using bias-corrected,
nonparametric bootstrapping (repeat re-sampling) [40].
Despite the skewed nature of cost data, this approach is
recommended to enable inferences to be made about
the arithmetic mean [41]. In a secondary analysis, cost-
effectiveness will be assessed through the calculation of
incremental cost-effectiveness ratios [42] and will be
explored in terms of global functioning (primary analy-
sis) and quality adjusted life years using the EQ-5 D
measure of health-related quality of life. Uncertainty
around the cost and effectiveness estimates will be
represented by cost-effectiveness acceptability curves
[43].
A full Statistical Analysis Plan was developed by the
team and ratified by an independent Trial Steering
Group prior to data analysis.
Discussion
The MATISSE trial provides the first opportunity to
examine the effects and cost effectiveness of group Art
Therapy compared to an active control treatment for
people with schizophrenia. In comparing outcomes of
those referred to group Art Therapy with those of peo-
ple referred to an activity group, we will be able to com-
pare levels of engagement with these different types of
groups and to explore whether any benefit associated
with group Art Therapy goes beyond that associated
with referral to a less specialised group. By collecting
follow-up data 24 months after randomisation we will
also be able to examine any long term benefit associated
with referral for group Art Therapy.
Since starting the trial national guidance on the treat-
ment of schizophrenia in England has been published
which recommend that clinicians should consider offer-
ing arts therapies to all people with schizophrenia, parti-
cularly for the alleviation of negative symptoms [19].
This recommendation is based on a synthesis of findings
from exploratory trials of a range of different individual
and group-based arts therapies. The MATISSE study
provides an opportunity to examine the impact of an
arts therapy when offered to a wider group of people
with schizophrenia across a range of different clinical
settings.
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Status of the trial
Recruitment to the study commenced in January 2007
and ended in September 2008. Four-hundred and seven-
teen participants were recruited and the final follow-up
interviews are due to be completed by September 2010.
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